Revolutionizing Diabetes and Obesity Management: A Comprehensive Review of Tirzepatide’s Dual Agonist Approach

Tirzepatide, an innovative glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, has emerged as a promising therapeutic avenue for type 2 diabetes and obesity management. This review encompasses a comprehensive evaluation of Tirzepatide’s mechanism of action, clinical efficacy, safety...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	JK Science
المؤلفون الرئيسيون:	Sonam Samal, Sourav Maiti, Jonnalagadda Vihari
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Dr. Annil Mahajan 2024-04-01
الموضوعات:	Tirzepatide Glucagon-like Peptide-1 (GLP-1) Glucagon Receptor Dual Agonist Diabetes Obesity
الوصول للمادة أونلاين:	https://journal.jkscience.org/index.php/JK-Science/article/view/266

مواد مشابهة

Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
حسب: Qingyue Zeng, وآخرون
منشور في: (2023-10-01)

Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
حسب: Qingyue Zeng, وآخرون
منشور في: (2024-03-01)

A systematic review of the safety of tirzepatide-a new dual GLP1 and GIP agonist - is its safety profile acceptable?
حسب: Zhuqing Meng, وآخرون
منشور في: (2023-03-01)

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review
حسب: Bartłomiej Stachyra, وآخرون
منشور في: (2023-04-01)

Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
حسب: Mohammad Amin Karimi, وآخرون
منشور في: (2025-05-01)

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
حسب: Rachel Sinha, وآخرون
منشور في: (2023-03-01)

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
حسب: Alexandros Leonidas Liarakos, وآخرون
منشور في: (2023-07-01)

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
حسب: Patrycja Kupnicka, وآخرون
منشور في: (2024-11-01)

State‐Level Variation in Glucagon‐Like Peptide‐1 Receptor Agonists Fills and Spending by Obesity Prevalence, 2023
حسب: Tamkeen Khan, وآخرون
منشور في: (2025-08-01)

Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight
حسب: Claire H. Feetham, وآخرون
منشور في: (2025-09-01)

G protein-coupled receptors and obesity
حسب: Alessandro Pocai
منشور في: (2023-12-01)

Application of GLP-1 receptor agonists in postoperative combined therapy for obesity: a perspective of metabolic surgery
حسب: MENG Hua, SONG Yujia, WANG Siqi
منشور في: (2025-05-01)

Tirzepatide - role in obesity, health and physical wellness. Information overview
حسب: Anna Hanslik, وآخرون
منشور في: (2025-02-01)

Tirzepatide for type 2 diabetes
حسب: Sarah L Anderson, وآخرون
منشور في: (2023-08-01)

The Effects of Tirzepatide on Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
حسب: Muhammad Umar Mahar, وآخرون
منشور في: (2024-12-01)

Frequently asked questions to the 2023 Obesity Medicine Association Position Statement on Compounded Peptides: A call for action
حسب: Harold Edward Bays, وآخرون
منشور في: (2024-09-01)

GLP-1 and Its Role in Glycogen Production: A Narrative Review
حسب: Joseph Lotosky, وآخرون
منشور في: (2025-06-01)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
حسب: A. Delgado, وآخرون
منشور في: (2021-04-01)

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait
حسب: Saleh Alali, وآخرون
منشور في: (2025-05-01)

Emerging glucagon-based therapies in diabetes mellitus: Toward a better future in diabetes care
حسب: Shahini Winson Gnanathayalan, وآخرون
منشور في: (2024-01-01)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
حسب: Alorfi NM, وآخرون
منشور في: (2022-08-01)

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
حسب: Cheney C, وآخرون
منشور في: (2025-05-01)

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension
حسب: Hae Young Lee, وآخرون
منشور في: (2024-09-01)

Effects of GLP-1 Receptor Polymorphisms on Adolescent Obesity
حسب: Mahafarin Maralani, وآخرون
منشور في: (2023-07-01)

Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
حسب: Ekaterina V. Tikhonenko, وآخرون
منشور في: (2018-12-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
حسب: Karolina Baran, وآخرون
منشور في: (2024-12-01)

Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
حسب: Bruno Vergès, وآخرون
منشور في: (2022-11-01)

Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
حسب: Haijun Wan, وآخرون
منشور في: (2024-11-01)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
حسب: Khang Duy Ricky Le, وآخرون
منشور في: (2024-01-01)

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
حسب: Tina Zimmermann, وآخرون
منشور في: (2022-12-01)

The Use of GLP-1 Receptor Agonists in the Treatment of Obesity in Women with PCOS
حسب: Aleksandra Jaroń, وآخرون
منشور في: (2024-08-01)

Maturity‐Onset Diabetes of the Young (MODY) With HNF1B p.Glu105Lys Mutation Achieving Significant Insulin Reduction on Tirzepatide: A Case Report
حسب: Mihiro Sue, وآخرون
منشور في: (2025-02-01)

Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
حسب: Qian Zhou, وآخرون
منشور في: (2023-10-01)

Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
حسب: Michal Rabenda, وآخرون
منشور في: (2024-08-01)

Onboarding obesity management in cardiovascular care: A cardiologist's guide to latest advances
حسب: François Schiele, وآخرون
منشور في: (2025-06-01)

Will Tirzepatide become a game-changer in the pharmacological treatment of obesity? - literature review
حسب: Aleksandra Doryń, وآخرون
منشور في: (2024-05-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
حسب: Marta Seghieri, وآخرون
منشور في: (2018-11-01)

Efficacy and Safety of Glucagon Like Peptide-1 Receptor Agonism Based Therapies in Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis
حسب: Deep Dutta, وآخرون
منشور في: (2025-01-01)

Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
حسب: Isabella Zaffina, وآخرون
منشور في: (2023-02-01)

Appendicitis After Initiation of Tirzepatide
حسب: Chan G, وآخرون
منشور في: (2025-01-01)